ArticleBMC cancer2025

Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).

Daniel Marbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.